The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

July 15, 2025

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Teriflunomide

Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.

DRUG

Danazol

200 mg twice daily.

Trial Locations (1)

100010

RECRUITING

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Luhe Hospital

OTHER

collaborator

Chinese PLA General Hospital

OTHER

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Beijing Hospital

OTHER_GOV

collaborator

Beijing Friendship Hospital

OTHER

collaborator

Peking University First Hospital

OTHER

collaborator

Peking University Third Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Beijing Tsinghua Changgeng Hospital

OTHER

lead

Peking University People's Hospital

OTHER